Top

International Journal of Colorectal Disease

Published in:

01-05-2007 | Original Article

Different matrix micro-environments in colon cancer and diverticular disease

Authors: U. Klinge, R. Rosch, K. Junge, C. J. Krones, M. Stumpf, P. Lynen-Jansen, P. R. Mertens, V. Schumpelick

Published in: International Journal of Colorectal Disease | Issue 5/2007

Abstract

Background and aims

The extracellular matrix and the interactive signalling between its components are thought to play a pivotal role for tumour development and metastasis formation. An altered matrix composition as potential underlying pathology for the development of colorectal cancer was hypothesized.

Methods

In a retrospective study of patients with colon cancer, the extracellular matrix in tumour-free bowel specimen was investigated in comparison with non-infected bowel specimen from patients operated on for colonic diverticulosis. The following matrix parameters with known associations to tumour formation, cell proliferation, invasion and metastasis were analysed by immunohistochemistry and quantified by a scoring system: VEGF, TGF-β, ESDN, CD117, c-erb-2, cyclin D1, p53, p27, COX-2, YB-1, collagen I/III, MMP-13, PAI and uPAR. Expression profiles and correlations were calculated.

Results

The comparison of the two groups revealed a significantly decreased immunostaining for CD117 and TGF-β in the cancer group (8.5±2.6 vs 10.3±2,1 and 4.9±1.5 vs 8.1±3, respectively), whereas PAI scores were significantly higher than in patients with diverticular disease (8.1±1.6 vs 6.2±0.9). Overall correlation patterns of matrix parameters indicated pronounced differences between tumour-free tissue in cancer patients compared with patients with diverticular disease.

Conclusions

Our results indicate distinct differences in the colonic tissue architecture between cancer patients and patients with diverticulitis that support the notion of an altered matrix composition predisposing to the development of colon cancer.

Krones CJ, Klinge U, Butz N, Junge K, Stumpf M, Rosch R, Hermanns B, Heussen N, Schumpelick V (2006) The rare epidemiologic coincidence of diverticular disease and advanced colonic neoplasia. Int J Colorectal Dis 21:18–24PubMedCrossRef

Paget S (1889) The distribution of secondary growths in cancer of the breast. Lancet 571–173

Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, Richardson A, Weinberg RA (2004) Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 101:4966–4971PubMedCrossRef

Bhowmick NA, Chytil A, Plieth D, Gorska AE, Dumont N, Shappell S, Washington MK, Neilson EG, Moses HL (2004) TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science 303:848–851PubMedCrossRef

Kinzler KW, Vogelstein B (1998) Landscaping the cancer terrain. Science 280:1036–1037PubMedCrossRef

Radisky DC, Bissell MJ (2004) Cancer. Respect thy neighbor! Science 303:775–777PubMedCrossRef

Glade-Bender J, Kandel JJ, Yamashiro DJ (2003) VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 3:263–276PubMedCrossRef

Skobe M, Rockwell P, Goldstein N, Vosseler S, Fusenig NE (1997) Halting angiogenesis suppresses carcinoma cell invasion. Nat Med 3:1222–1227PubMedCrossRef

Salgaller ML (2003) Technology evaluation: bevacizumab, Genentech/Roche. Curr Opin Mol Ther 5:657–667PubMed

10.

Zondor SD, Medina PJ (2004) Bevacizumab: an angiogenesis inhibitor with efficacy in colorectal and other malignancies. Ann Pharmacother 38:1258–1264PubMedCrossRef

11.

Lohr M, Schmidt C, Ringel J, Kluth M, Muller P, Nizze H, Jesnowski R (2001) Transforming growth factor-beta1 induces desmoplasia in an experimental model of human pancreatic carcinoma. Cancer Res 61:550–555PubMed

12.

Becker C, Fantini MC, Schramm C, Lehr HA, Wirtz S, Nikolaev A, Burg J, Strand S, Kiesslich R, Huber S, Ito H, Nishimoto N, Yoshizaki K, Kishimoto T, Galle PR, Blessing M, Rose-John S, Neurath MF (2004) TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling. Immunity 21:491–501PubMedCrossRef

13.

Kobuke K, Furukawa Y, Sugai M, Tanigaki K, Ohashi N, Matsumori A, Sasayama S, Honjo T, Tashiro K (2001) ESDN, a novel neuropilin-like membrane protein cloned from vascular cells with the longest secretory signal sequence among eukaryotes, is up-regulated after vascular injury. J Biol Chem 276:34105–34114PubMedCrossRef

14.

Tsuura Y, Hiraki H, Watanabe K, Igarashi S, Shimamura K, Fukuda T, Suzuki T, Seito T (1994) Preferential localization of c-kit product in tissue mast cells, basal cells of skin, epithelial cells of breast, small cell lung carcinoma and seminoma/dysgerminoma in human: immunohistochemical study on formalin-fixed, paraffin-embedded tissues. Virchows Arch 424:135–141PubMedCrossRef

15.

de Silva CM, Reid R (2003) Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathol Oncol Res 9:13–19PubMedCrossRef

16.

Pinto-de-Sousa J, David L, Almeida R, Leitao D, Preto JR, Seixas M, Pimenta A (2002) c-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 10:247–256PubMed

17.

Half E, Broaddus R, Danenberg KD, Danenberg PV, Ayers GD, Sinicrope FA (2004) HER-2 receptor expression, localization, and activation in colorectal cancer cell lines and human tumors. Int J Cancer 108:540–548PubMedCrossRef

18.

Yang JL, Hanley JR, Yu Y, Berney CR, Russell PJ, Crowe PJ (1997) In vivo overexpression of c-erbB-2 oncoprotein in xenografts of mice implanted with human colon cancer lines. Anticancer Res 17:3463–3468PubMed

19.

Lukas J, Pagano M, Staskova Z, Draetta G, Bartek J (1994) Cyclin D1 protein oscillates and is essential for cell cycle progression in human tumour cell lines. Oncogene 9:707–718PubMed

20.

Bartkova J, Lukas J, Strauss M, Bartek J (1995) Cyclin D1 oncoprotein aberrantly accumulates in malignancies of diverse histogenesis. Oncogene 10:775–778PubMed

21.

Kim SH, Lewis JJ, Brennan MF, Woodruff JM, Dudas M, Cordon-Cardo C (1998) Overexpression of cyclin D1 is associated with poor prognosis in extremity soft-tissue sarcomas. Clin Cancer Res 4:2377–2382PubMed

22.

Harris CC (1996) Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88:1442–1455PubMedCrossRef

23.

Resnick MB, Routhier J, Konkin T, Sabo E, Pricolo VE (2004) Epidermal growth factor receptor, c-MET, beta-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study. Clin Cancer Res 10:3069–3075PubMedCrossRef

24.

Lloyd RV, Erickson LA, Jin L, Kulig E, Qian X, Cheville JC, Scheithauer BW (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am J Pathol 154:313–323PubMed

25.

Blain SW, Scher HI, Cordon-Cardo C, Koff A (2003) p27 as a target for cancer therapeutics. Cancer Cell 3:111–115PubMedCrossRef

26.

Rao CV, Cooma I, Rodriguez JG, Simi B, El Bayoumy K, Reddy BS (2000) Chemoprevention of familial adenomatous polyposis development in the APC(min) mouse model by 1,4-phenylene bis(methylene)selenocyanate. Carcinogenesis 21:617–621PubMedCrossRef

27.

Rao CV, Indranie C, Simi B, Manning PT, Connor JR, Reddy BS (2002) Chemopreventive properties of a selective inducible nitric oxide synthase inhibitor in colon carcinogenesis, administered alone or in combination with celecoxib, a selective cyclooxygenase-2 inhibitor. Cancer Res 62:165–170PubMed

28.

Reddy BS, Rao CV, Seibert K (1996) Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res 56:4566–4569PubMed

29.

Shibao K, Takano H, Nakayama Y, Okazaki K, Nagata N, Izumi H, Uchiumi T, Kuwano M, Kohno K, Itoh H (1999) Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer 83:732–737PubMedCrossRef

30.

Kamura T, Yahata H, Amada S, Ogawa S, Sonoda T, Kobayashi H, Mitsumoto M, Kohno K, Kuwano M, Nakano H (1999) Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 85:2450–2454PubMedCrossRef

31.

Shibahara K, Sugio K, Osaki T, Uchiumi T, Maehara Y, Kohno K, Yasumoto K, Sugimachi K, Kuwano M (2001) Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7:3151–3155PubMed

32.

Menke A, Philippi C, Vogelmann R, Seidel B, Lutz MP, Adler G, Wedlich D (2001) Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic cancer cell lines. Cancer Res 61:3508–3517PubMed

33.

Stumpf M, Cao W, Klinge U, Klosterhalfen B, Kasperk R, Schumpelick V (2001) Increased distribution of collagen type III and reduced expression of matrix metalloproteinase 1 in patients with diverticular disease. Int J Colorectal Dis 16:271–275PubMedCrossRef

34.

Roeb E, Matern S (2003) Matrix metalloproteinases and colorectal cancer (in German). Med Klin (Munich) 98:763–770CrossRef

35.

Davies B, Waxman J, Wasan H, Abel P, Williams G, Krausz T, Neal D, Thomas D, Hanby A, Balkwill F (1993) Levels of matrix metalloproteases in bladder cancer correlate with tumor grade and invasion. Cancer Res 53:5365–5369PubMed

36.

Matrisian LM, Wright J, Newell K, Witty JP (1994) Matrix-degrading metalloproteinases in tumor progression. Princess Takamatsu Symp 24:152–161PubMed

37.

Duffy MJ (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10:39–49PubMedCrossRef

38.

Duffy MJ (1992) The role of proteolytic enzymes in cancer invasion and metastasis. Clin Exp Metastasis 10:145–155PubMedCrossRef

39.

Romer J, Nielsen BS, Ploug M (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des 10:2359–2376PubMedCrossRef

40.

Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM (1998) Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4:923–928PubMedCrossRef

41.

Yonemura Y, Nojima N, Kaji M, Fujimura T, Itoh H, Ninomiya I, Miyazaki I, Endo Y, Sasaki T (1995) E-cadherin and urokinase-type plasminogen activator tissue status in gastric carcinoma. Cancer 76:941–953PubMedCrossRef

42.

Nekarda H, Schmitt M, Ulm K, Wenninger A, Vogelsang H, Becker K, Roder JD, Fink U, Siewert JR (1994) Prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in completely resected gastric cancer. Cancer Res 54:2900–2907PubMed

43.

Chambers SK, Ivins CM, Carcangiu ML (1998) Plasminogen activator inhibitor-1 is an independent poor prognostic factor for survival in advanced stage epithelial ovarian cancer patients. Int J Cancer 79:449–454PubMedCrossRef

44.

Remmele WSH (1987) Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8:138–140PubMed

45.

Stumpf M, Klinge U, Wilms A, Zabrocki R, Rosch R, Junge K, Krones C, Schumpelick V (2005) Changes of the extracellular matrix as a risk factor for anastomotic leakage after large bowel surgery. Surgery 137:229–234PubMedCrossRef

46.

Fidler IJ (2002) The organ microenvironment and cancer metastasis. Differentiation 70:498–505PubMedCrossRef

47.

Liotta LA, Kohn EC (2001) The microenvironment of the tumour–host interface. Nature 411:375–379PubMedCrossRef

48.

Mueller MM, Fusenig NE (2004) Friends or foes—bipolar effects of the tumour stroma in cancer. Nat Rev Cancer 4:839–849PubMedCrossRef

49.

Aboseif S, El Sakka A, Young P, Cunha G (1999) Mesenchymal reprogramming of adult human epithelial differentiation. Differentiation 65:113–118PubMedCrossRef

50.

Li Y, Liu W, Hayward SW, Cunha GR, Baskin LS (2000) Plasticity of the urothelial phenotype: effects of gastro-intestinal mesenchyme/stroma and implications for urinary tract reconstruction. Differentiation 66:126–135PubMedCrossRef

51.

Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR (1999) Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res 59:5002–5011PubMed

52.

Peek RM, Blaser MJ Jr (2002) Helicobacter pylori and gastrointestinal tract adenocarcinomas. Nat Rev Cancer 2:28–37PubMedCrossRef

53.

Farrell RJ, Peppercorn MA (2002) Ulcerative colitis. Lancet 359:331–340PubMedCrossRef

54.

Mukaratirwa S, Koninkx JF, Gruys E, Nederbragt H (2005) Mutual paracrine effects of colorectal tumour cells and stromal cells: modulation of tumour and stromal cell differentiation and extracellular matrix component production in culture. Int J Exp Pathol 86:219–229PubMedCrossRef

55.

Bellone G, Silvestri S, Artusio E, Tibaudi D, Turletti A, Geuna M, Giachino C, Valente G, Emanuelli G, Rodeck U (1997) Growth stimulation of colorectal carcinoma cells via the c-kit receptor is inhibited by TGF-beta 1. J Cell Physiol 172:1–11PubMedCrossRef

56.

Xie XY, Carter N, Darwin PE, Drachenberg CB (2004) Gastrointestinal stromal tumors: update. Arkh Patol 66:36–40PubMed

Title: Different matrix micro-environments in colon cancer and diverticular disease
Authors: U. Klinge
R. Rosch
K. Junge
C. J. Krones
M. Stumpf
P. Lynen-Jansen
P. R. Mertens
V. Schumpelick
Publication date: 01-05-2007
Publisher: Springer-Verlag
Published in: International Journal of Colorectal Disease / Issue 5/2007
Print ISSN: 0179-1958
Electronic ISSN: 1432-1262
DOI: https://doi.org/10.1007/s00384-006-0199-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Different matrix micro-environments in colon cancer and diverticular disease

Abstract

Background and aims

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background and aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 5/2007

Colorectal cancer screening coverage in Greece. PACMeR 02.01 study collaboration

HER-2/neu overexpression is an independent prognostic factor in colorectal cancer

A systematic review of the function and complications of colonic pouches

Haemorrhagic shock caused by splenic rupture following routine colonoscopy

Intensified neoadjuvant radiochemotherapy for locally advanced rectal cancer: a review

Preoperative radiation therapy for locally advanced rectal cancer: a comparison between two different time intervals to surgery